PCA Investment Advisory Services Inc. Invests $46,000 in Cerus Co. (NASDAQ:CERS)

PCA Investment Advisory Services Inc. purchased a new stake in shares of Cerus Co. (NASDAQ:CERS) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 30,000 shares of the biotechnology company’s stock, valued at approximately $46,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Geode Capital Management LLC boosted its position in Cerus by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,415,453 shares of the biotechnology company’s stock valued at $7,685,000 after acquiring an additional 69,950 shares in the last quarter. Barclays PLC boosted its position in shares of Cerus by 16.2% during the third quarter. Barclays PLC now owns 1,575,049 shares of the biotechnology company’s stock valued at $2,740,000 after purchasing an additional 219,755 shares in the last quarter. State Street Corp grew its stake in Cerus by 2.2% in the third quarter. State Street Corp now owns 3,738,893 shares of the biotechnology company’s stock worth $6,506,000 after purchasing an additional 79,505 shares during the period. Stifel Financial Corp raised its holdings in Cerus by 12.0% in the third quarter. Stifel Financial Corp now owns 264,672 shares of the biotechnology company’s stock worth $461,000 after purchasing an additional 28,383 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in Cerus by 13.8% during the third quarter. Franklin Resources Inc. now owns 93,763 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 11,338 shares during the period. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Cerus Stock Up 5.7 %

Shares of NASDAQ:CERS opened at $1.67 on Tuesday. Cerus Co. has a 12-month low of $1.38 and a 12-month high of $2.59. The stock has a market capitalization of $310.14 million, a price-to-earnings ratio of -15.18 and a beta of 1.27. The stock has a fifty day simple moving average of $1.71 and a two-hundred day simple moving average of $1.89. The company has a current ratio of 2.59, a quick ratio of 1.92 and a debt-to-equity ratio of 1.19.

Insider Transactions at Cerus

In other Cerus news, Director Eric Bjerkholt sold 20,000 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $1.78, for a total transaction of $35,600.00. Following the sale, the director now directly owns 162,133 shares in the company, valued at approximately $288,596.74. This trade represents a 10.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 3.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus decreased their price target on shares of Cerus from $6.00 to $3.00 and set a “buy” rating for the company in a research note on Thursday, October 17th.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.